Literature DB >> 29332584

Multicomponent Reactions for Multitargeted Compounds for Alzheimer`s Disease.

Lhassane Ismaili1, Maria do Carmo Carreiras2.   

Abstract

Alzheimer's Disease (AD) is a multifactorial and fatal neurodegenerative disorder affecting around 35 million people worldwide, which is characterized by decline of cholinergic function, deregulation of amyloid beta (Aβ) oligomers formation and Aβ fibril deposition. Multi-Target- Directed Ligands (MTDLs) have emerged as an original strategy for developing new therapeutic agents on AD. Multicomponent Reactions (MCRs) are a useful alternative to sequential multistep syntheses, allowing scaffold diversity and a rapid and easy access to biologically relevant compounds. The biological diversity of MCRs is very rich providing great possibilities for researchers interested in bioactive small molecular weight compounds. Since the MTDL strategy has been used to develop compounds endowed with the capacity to interact with different targets, versatile compound libraries may be obtained by MCRs according to the well established features of each target. Thus, either MTDLs or monotarget compounds have been developed by MCRs to address different factors implicated in AD. This work focuses on antioxidants, calcium channel modulators, both AChE and BuChE inhibitors, BACE1 inhibitors, and modulators of the nuclear factor (erythroid-derived 2)-like 2. First, we discuss the Biginelli reaction and its use for developing new interesting compounds for AD, followed by the contribution of Ugi reaction and, finally, the interest of other MCRs in the same topic. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer's Disease; Biginelli reaction.; Multi-target-Directed Ligands; Multicomponent reactions; Multitargeted compounds; Ugizzm321990reaction

Mesh:

Substances:

Year:  2017        PMID: 29332584     DOI: 10.2174/1568026618666180112155424

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  4 in total

1.  Triazolopyridopyrimidine: A New Scaffold for Dual-Target Small Molecules for Alzheimer's Disease Therapy.

Authors:  Lazhar Zribi; Irene Pachòn-Angona; Òscar M Bautista-Aguilera; Daniel Diez-Iriepa; José Marco-Contelles; Lhassane Ismaili; Isabel Iriepa; Fakher Chabchoub
Journal:  Molecules       Date:  2020-07-13       Impact factor: 4.411

2.  Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy.

Authors:  Irene Pachón-Angona; Bernard Refouvelet; Rudolf Andrýs; Helène Martin; Vincent Luzet; Isabel Iriepa; Ignacio Moraleda; Daniel Diez-Iriepa; María-Jesús Oset-Gasque; José Marco-Contelles; Kamil Musilek; Lhassane Ismaili
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

3.  Design, Synthesis and Biological Evaluation of New Antioxidant and Neuroprotective Multitarget Directed Ligands Able to Block Calcium Channels.

Authors:  Irene Pachòn Angona; Solene Daniel; Helene Martin; Alexandre Bonet; Artur Wnorowski; Maciej Maj; Krzysztof Jóźwiak; Tiago Barros Silva; Bernard Refouvelet; Fernanda Borges; José Marco-Contelles; Lhassane Ismaili
Journal:  Molecules       Date:  2020-03-14       Impact factor: 4.411

4.  Synthesis of Hantzsch Adducts as Cholinesterases and Calcium Flux inhibitors, Antioxidants and Neuroprotectives.

Authors:  Irene Pachón Angona; Helene Martin; Solene Daniel; Ignacio Moraleda; Alexandre Bonet; Artur Wnorowski; Maciej Maj; Krzysztof Jozwiak; Isabel Iriepa; Bernard Refouvelet; José Marco-Contelles; Lhassane Ismaili
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.